相关实验视频

Updated: Jan 18, 2026

Lipidomics and Transcriptomics in Neurological Diseases

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

铁素模仿性可以减轻的进展和神经认知缺陷

Prince Kumar Singh¹, Shweta Maurya¹, Aseel Saadi¹

¹The Institute for Drug Research, The School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, - 91120, Israel.

|January 16, 2026

概括

作为一种疾病修饰性疗法,TXM-CB3 (CB3) 是一个有前途的疗法. 这种 thioredoxin-mimetic tripeptide 减少了发作,保护了神经元,并在临床前模型中改善了行为,提供了超越当前治疗的好处.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.

背景情况:

是一种慢性神经系统疾病,经常出现发作.
氧化应激和神经炎症是进展和药物耐药性的关键驱动因素.
目前的抗发作药物 (ASM) 在30%-40%的患者中具有有限的疗效,这凸显了对疾病修饰疗法的需要.

研究的目的:

在临床前模型中评估TXM-CB3 (CB3),一种 thioredoxin-mimetic三的治疗潜力.
评估CB3抑制发作,保持神经元完整性和减轻相关行为障碍的能力.

主要方法:

在体外:评估CB3对低Mg2+诱导的型活动,氧化应激和细胞因子表达的影响.
在体内:在凯尼克酸诱导的叶模型中评估了早期和慢性CB3干预.
测量了发作参数,神经元完整性,运动活动,焦虑类行为和空间工作记忆.

主要成果:

在体外,CB3减弱了氧化活性,减少了促炎性细胞因子 (IL-6,IL-1β,TNF-α),同时增加了IL-10.
早期体内干预延迟了发作,减少了发作的频率和负担,并保存了海马神经元.
在早期阶段,CB3治疗改善了运动活动,减少了焦虑,并增强了空间工作记忆;慢性治疗持续减少了发作和减少了焦虑.

结论:

作为的疾病修饰剂,TXM-CB3 (CB3) 显示出显著的治疗潜力.
CB3减少了发作的复发,保持了神经元的完整性,并减轻了行为缺陷,比传统的ASM提供了优势.
对CB3进行进一步的研究是必要的,以便在治疗中进行临床转化.

关键词:

这是一种CB3.改变疾病的疗法.是一种病.神经炎症是一种神经炎症.氧化应激是一种氧化应激.

更多相关视频

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Direct-current Stimulation and Multi-electrode Array Recording of Seizure-like Activity in Mice Brain Slice Preparation

Direct-current Stimulation and Multi-electrode Array Recording of Seizure-like Activity in Mice Brain Slice Preparation

Published on: June 7, 2016

相关概念视频

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Antiepileptic Drugs: Glutamate Antagonists

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Epilepsy and Seizures: Overview

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...